Because of advances in antiviral HBV/HCV therapies leading to improved liver function, post-treatment AFP levels stay normalized, rendering high specificity to AFP for HCC surveillance in patients with chronic inflammatory background,20 potentially making AFP-L3 usage obsolete.21 This evidence concerns the gene AFP and hepatocellular carcinoma.